Sichuan Goldstone Asia Pharmaceutical Inc. engages in the research, development, manufacture, and sale of medicines and health products in China and internationally. The company offers various pharmaceutical preparations and APIs; Chinese and western pharmaceutical preparations and raw materials; and tablets, capsules, dietary supplements, vitamin products, OTC products, and prescription drugs. It also trades in various pharmaceutical products, such as Chinese herbal medicine materials, Chinese patent medicines, Chinese herbal pieces, chemical raw materials, pharmaceutical preparations, antibiotic preparations, biochemical drugs, dietary supplements, and toxic drugs for medical use, medical devices, etc.; and sells adult drug products under the Quike brand and children's general medicine products under the Mini-Quike brand name. In addition, the company researches, develops, manufactures, and sells plastic composite pipe and vacuum coating machines. Further, it offers reinforced pipe equipment, such as steel reinforced corrugated pipes, reinforced composite polyethylene pipes, fiberglass reinforced RTP pipes, steel reinforced large diameter pipes, steel reinforced corrugated pipe socket and spigot making machines, abrasion resistant industries pipes, extrusion pipe fittings, and perforated steel reinforced polyethylene composite pipes. Additionally, the company provides vacuum coating equipment, including low-emissivity glass coating lines, reflect glass magnetron sputtering coating lines, magnetron sputtering mirror coating production lines, vacuum sputter systems for automotive car mirrors, ITO/TCO glass coating machines, sputtering metallization machines, optical lens coating machines, roll web metallization machines, and air-to-air solar absorption strip sputtering production line; and smart parking equipment. Sichuan Goldstone Asia Pharmaceutical Inc. was founded in 2001 and is based in Chengdu, China.
Sichuan Goldstone Asia Pharmaceutical Dividend Announcement
• Sichuan Goldstone Asia Pharmaceutical announced a annually dividend of ¥0.11 per ordinary share which will be made payable on 2024-06-28. Ex dividend date: 2024-06-28
• Sichuan Goldstone Asia Pharmaceutical annual dividend for 2024 was ¥0.11
• Sichuan Goldstone Asia Pharmaceutical's trailing twelve-month (TTM) dividend yield is 1.23%
• Sichuan Goldstone Asia Pharmaceutical's payout ratio for the trailing twelve months (TTM) is 98.93%
Sichuan Goldstone Asia Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-06-28 | ¥0.11 | annually | 2024-06-28 |
2020-08-11 | ¥0.07 | annually | 2020-08-11 |
2019-06-27 | ¥0.08 | annually | 2019-06-27 |
2018-07-17 | ¥0.11 | annually | 2018-07-17 |
2017-05-10 | ¥0.05 | annually | 2017-05-10 |
2016-06-17 | ¥0.10 | annually |
Sichuan Goldstone Asia Pharmaceutical Dividend per year
Sichuan Goldstone Asia Pharmaceutical Dividend growth
Sichuan Goldstone Asia Pharmaceutical Dividend Yield
Sichuan Goldstone Asia Pharmaceutical current trailing twelve-month (TTM) dividend yield is 1.23%. Interested in purchasing Sichuan Goldstone Asia Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Sichuan Goldstone Asia Pharmaceutical Financial Ratios
Sichuan Goldstone Asia Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Sichuan Goldstone Asia Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Sichuan Goldstone Asia Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Sichuan Goldstone Asia Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Sichuan Goldstone Asia Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Sichuan Goldstone Asia Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Sichuan Goldstone Asia Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Sichuan Goldstone Asia Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Sichuan Goldstone Asia Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Sichuan Goldstone Asia Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Sichuan Goldstone Asia Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Sichuan Goldstone Asia Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.